We are live on ! Find out more
ARTL icon

Artelo Biosciences

8 hedge funds and large institutions have $122K invested in Artelo Biosciences in 2026 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

271% more capital inflows, than outflows

Capital inflows: $147K | Capital outflows: $39.7K

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

14% more funds holding

Funds holding: 7 → 8 (+1)

10.39% less ownership

Funds ownership: 15.91% → 5.52% (-10%)

Holders
8
Holders Change
+1
Holders Change %
+14.29%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
4
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

ARTL Hedge Fund Activity: Q3 2026 in Review

8 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2026, worth a combined $122K — down 7.5% from $132K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ARTL positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $88.9K. The largest seller was Geode Capital Management, exiting entirely with an estimated $15.5K sold.

  • 8 institutional investors held Artelo Biosciences (ARTL) as of Q3 2026, up from 7 in Q2 2026.
  • Funds reported $122K of Artelo Biosciences stock for Q3 2026, down 7.5% quarter-over-quarter.
  • 4 funds opened new Artelo Biosciences positions in Q3 2026 and 3 closed out, a net change of +1 holder.
  • The largest Artelo Biosciences buyer in Q3 2026 was UBS Group, an estimated $88.9K added.
  • The largest Artelo Biosciences seller in Q3 2026 was Geode Capital Management, an estimated $15.5K sold.

Based on aggregated 13F filings for Q3 2026.